{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:20:53Z","timestamp":1791580853598,"version":"4.3.4"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T00:00:00Z","timestamp":1614988800000},"content-version":"am","delay-in-days":278,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.msard.2020.102019","type":"journal-article","created":{"date-parts":[[2020,2,22]],"date-time":"2020-02-22T11:15:52Z","timestamp":1582370152000},"page":"102019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases"],"prefix":"10.1016","volume":"41","author":[{"given":"J.","family":"Rigal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3386-6308","authenticated-orcid":false,"given":"J.","family":"Ciron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"L\u00e9pine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0569-629X","authenticated-orcid":false,"given":"D.","family":"Biotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.msard.2020.102019_bib0001","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1177\/1352458518765677","article-title":"Late-onset neutropenia and neurological relapse, during long-term rituximab therapy in myelin oligodendrocyte glycoprotein-antibody spectrum disorder","volume":"24","author":"Biotti","year":"2018","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.msard.2020.102019_bib0002","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1212\/WNL.0000000000006924","article-title":"Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis","volume":"92","author":"Cohen","year":"2019","journal-title":"Neurology"},{"issue":"10206","key":"10.1016\/j.msard.2020.102019_bib0003","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.msard.2020.102019_bib0004","first-page":"765","article-title":"Drug-Induced neutropenia: a focus on rituximab-induced late-onset neutropenia","volume":"41","author":"Moore","year":"2016","journal-title":"P T"},{"key":"10.1016\/j.msard.2020.102019_bib0006","unstructured":"Ocrevus full prescribing information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761053lbl.pdf. Accessed July 3, 2018."},{"issue":"7","key":"10.1016\/j.msard.2020.102019_bib0005","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.msard.2020.102019_bib0007","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.msard.2013.08.001","article-title":"Late-onset neutropenia during long-term rituximab therapy in neuromyelitis optica","volume":"3","author":"Plate","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102019_bib0008","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.msard.2017.12.005","article-title":"Severe neutropenia after rituximab-treatment of multiple sclerosis","volume":"20","author":"Rissanen","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2020.102019_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000034","article-title":"Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry","volume":"1","author":"Salmon","year":"2015","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.msard.2020.102019_bib0010","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1586\/ehm.11.62","article-title":"Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms","volume":"4","author":"Tesfa","year":"2011","journal-title":"Expert. Rev. Hematol."},{"key":"10.1016\/j.msard.2020.102019_bib0011","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/art.30427","article-title":"Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections","volume":"63","author":"Tesfa","year":"2011","journal-title":"Arthritis Rheum."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482030095X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482030095X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:47:57Z","timestamp":1761900477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482030095X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":11,"alternative-id":["S221103482030095X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102019","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102019"}}